Search
Search Results
-
Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer
BackgroundSolid tumors subjected to intermittent hypoxia are characterized by resistance to chemotherapy and immune-killing by effector...
-
Immuno-Oncology Crosstalk and Metabolism
This book discusses the novel metabolic cross-talk between immune and tumor cells in the tumor microenvironment that promotes their growth and...
-
Cancer Metastasis: Dynamic Hetero-cellular Communications Between Cancer Cells and Host Tissues
Metastasis is the most devastating aspect of cancer. Originally, tumor cells arise from a single clone, and then they undergo additional mutations...
-
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
Immunotherapies blocking the PD-1/PD-L1 checkpoint show some efficacy in metastatic breast cancer (mBC) but are often hindered by immunosuppressive...
-
Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation
Breast cancer (BC) is the most commonly diagnosed cancer among women. Chemo-, immune- and photothermal therapies are employed to manage BC. However,...
-
Perspectives in ROS/Redox Regulation Cancer Therapy
This chapter entitled “Perspectives in ROS/Redox Regulation Cancer Therapy” discusses the status of redox regulation anticancer therapy, its lacunae,...
-
Role of Nano-immunotherapy in Colorectal Cancer: An Updated Review
Colorectal cancer (CRC) has become the leading cause of death among cancer patients in developed countries. Genetic and environmental factors, along...
-
Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway
The aberrantly up-regulated CDK9 can be targeted for cancer therapy. The CDK inhibitor dinaciclib (Dina) has been found to drastically sensitizes...
-
Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer
Immune checkpoint blockade has drastically changed the way that cancer is treated, and it also gives cancer patients hope for the future. However, a...
-
Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?
Tumor-infiltrating lymphocytes (TIL) are an important prognostic factor of the antitumor therapy effectiveness and the course of the malignant...
-
Evolution of Lung Cancer Treatment from Classical Chemotherapy to Advanced Immunotherapy
Lung cancer is the second most common cancer across the globe. According to SEER (Surveillance, Epidemiology, and End Result), the survival rate of...
-
Current Treatment Approaches to Breast Cancer
Breast cancer is a familiar malignancy and the major reason for cancer mortality among females worldwide. Research on breast carcinoma has led to...
-
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
BackgroundImmune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless,...
-
Role of EFGR in Medulloblastoma Development
EGFR expression was detected in primitive neuro-ectodermal tumor-derived TE-671 tissue culture cell line. This expression was determined based on a...
-
Vincristine-based nanoformulations: a preclinical and clinical studies overview
Vincristine (VCR) is a chemotherapeutic agent obtained from natural alkaloid plant source Catharanthus roseus. VCR has been significantly useful in...
-
Nanotechnologies in Oncology
Nano-oncology, the application of nanomedicine to cancer treatments, has the potential to transform clinical oncology by enhancing the efficacy of...
-
Nanotechnologies in Oncology
Nano-oncology, the application of nanomedicine to cancer treatments, has the potential to transform clinical oncology by enhancing the efficacy of...
-
Precision Medicine in Therapy of Non-solid Cancer
The development and approval of the tyrosine kinase inhibitor imatinib in 2001 has heralded the advance of directed therapy options. Today, an...
-
Nanoparticles in Cancer Therapy
In the realm of cancer therapy, nanoparticles have emerged as a pioneering avenue, ushering in a remarkable journey filled with breakthroughs and...
-
Intercellular Communication in Cancer
Junctional complexes play a central role in maintaining tissue hemostasis. The barrier function of epithelial cells, that maintain tissues coherence...